Stories
Slash Boxes
Comments

SoylentNews is people

SoylentNews is powered by your submissions, so send in your scoop. Only 10 submissions in the queue.
posted by janrinok on Thursday October 15 2015, @01:03PM   Printer-friendly
from the money-makes-the-world-go-round dept.

U.S. prices for the world's 20 top-selling medicines are, on average, three times higher than in Britain, according to an analysis carried out for Reuters.

The finding underscores a transatlantic gulf between the price of treatments for a range of diseases and follows demands for lower drug costs in America from industry critics such as Democratic presidential candidate Hillary Clinton.

The 20 medicines, which together accounted for 15 percent of global pharmaceuticals spending in 2014, are a major source of profits for companies including AbbVie (ABBV.N), AstraZeneca (AZN.L), Merck (MRK.N), Pfizer (PFE.N) and Roche (ROG.VX).


Original Submission

 
This discussion has been archived. No new comments can be posted.
Display Options Threshold/Breakthrough Mark All as Read Mark All as Unread
The Fine Print: The following comments are owned by whoever posted them. We are not responsible for them in any way.
  • (Score: 2) by bradley13 on Thursday October 15 2015, @02:42PM

    by bradley13 (3053) on Thursday October 15 2015, @02:42PM (#249988) Homepage Journal

    The US does not have a free market for health care, silly. It didn't before Obamacare, and it surely doesn't with Obamacare.

    Switzerland, where I live, used to have a pretty free market. About 15 years ago they put in a milder version of what the US now has. My health insurance costs immediately doubled, and have gone up around 5% every year since. That's what the US is now seeing, only apparently even more extreme.

    It's well-meaning, but make something 'free' and people will abuse it.

    --
    Everyone is somebody else's weirdo.
    Starting Score:    1  point
    Karma-Bonus Modifier   +1  

    Total Score:   2  
  • (Score: 0) by Anonymous Coward on Thursday October 15 2015, @07:57PM

    by Anonymous Coward on Thursday October 15 2015, @07:57PM (#250180)

    You might be interpreting free market differently than I do, but surely the US market for now is still pretty free. Allow me to illustrate.

    Valeant is a Canadian-based drug company that, like most other pharmaceutical companies, offers financial assistance to poor patients who can ill afford their drugs.
    This kind of direct financial assistance to patients is, however, not allowed under Medicare/Medicaid. To work around that, Valeant (and other companies) donate money to independent foundations, who then provide assistance to those patients. On October 15, Valeant found itself on the receiving end of subpoenas issued by the US attorney's offices of Manhattan and Massachusetts.

    The company itself stated that it are those very assistance programs which are chiefly under investigation. Noteworthy though is that the subpoenas require details about Valeant's pricing policies and the distribution of its drugs. This is interesting, as Valeant is also known* as being involved in buy-and-raise practices: buying up an old drug, than raising the price.

    Two examples, for this year alone, are the buying up of two life-saving heart drugs (Nitropress, Isuprel) -- whose prices subsequently increased with 525 and 212 percent respectively. In defense of the company, it must be said that those price increases are rather modest -- in comparison to competitors in the market**.

    When Turing Pharmaceuticals ("developing and commercializing innovative treatments") acquired the rights to Daraprim in August this year -- a drug often given to cancer and Aids patients -- it jacked up its price 55-fold overnight, from $13.50 to $750 a pill.

    It took an angry tweet from a certain Democratic presidential candidate for Turing to jack down the price again to -- if a recent press release [turingpharma.com] is to be believed -- 10 dollar a prescription. Like Valeant, Turing too now find itself under investigation [nytimes.com] by New York's attorney general.

    It is a bit of a shame, ofcourse, for the rest of the biotech and pharmaceuticals industry -- where shares went down together with the bad news for both companies: odd, no?

    *Valeant shares dive after pricing probe, Financial Times, Oct 15
    **Big Pharma thinks twice about jacking up prices, Financial Times, Oct 8